Literature DB >> 3030540

Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.

J Markovits, Y Pommier, D Kerrigan, J M Covey, E J Tilchen, K W Kohn.   

Abstract

The DNA intercalator, 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and the nonintercalator, etoposide (VP-16) produce topoisomerase II-mediated protein-linked DNA strand breaks. This function of topoisomerase II was investigated in relation to cell proliferation and cell cycle. Mouse fibroblasts NIH 3T3 and mouse leukemia L1210 cells stop proliferation when they reach a certain density. Nuclei were isolated from proliferative or quiescent cells and then treated with drug for 30 min. DNA modifications were assayed by alkaline elution. We found that the frequencies of m-AMSA- or VP-16-induced DNA-protein links were higher in nuclei from exponentially growing than in those from quiescent cells in both the 3T3 and the L1210 lines. Drug-induced protein-associated DNA breaks were also studied as a function of the cell cycle in 3T3 cells that had been arrested by contact inhibition in medium containing 1% calf serum and then stimulated to proliferate by raplating at a lower cell density in medium containing 10% serum. In these synchronized cells, a large peak of [3H]thymidine incorporation occurred 18-30 h after replating. The yield of DNA-protein cross-links produced by 30-min drug treatments of nuclei isolated at various times after growth initiation increased concomitantly with the peak of the DNA synthesis. The topoisomerase II activity of nuclear extracts, as measured by kinetoplast DNA decatenation followed a similar pattern. Using colony-forming assays, we also observed that m-AMSA and VP-16 were most cytotoxic in proliferative cells and during DNA synthesis. These results suggest that alkaline elution measurement of m-AMSA- or VP-16-induced protein-linked DNA breaks reflects the association of topoisomerase II with DNA. This association is increased during DNA replication, making the cells more vulnerable to m-AMSA and VP-16 at this time.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030540

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Topoisomerase II-mediated alterations of K562 drug resistant sublines.

Authors:  R Zhou; Y Wang; A Gruber; R Larsson; E Castaños-Vèlez; E Liliemark
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

2.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 3.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

4.  New insights into tumor dormancy: Targeting DNA repair pathways.

Authors:  Elizabeth B Evans; Shiaw-Yih Lin
Journal:  World J Clin Oncol       Date:  2015-10-10

5.  Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death.

Authors:  N A Berger; S Chatterjee; J A Schmotzer; S R Helms
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

6.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II.

Authors:  D A Burden; L J Goldsmith; D M Sullivan
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

8.  Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine.

Authors:  C M Chresta; R Hicks; J A Hartley; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia.

Authors:  Federica Falà; William L Blalock; Pier Luigi Tazzari; Alessandra Cappellini; Francesca Chiarini; Giovanni Martinelli; Agostino Tafuri; James A McCubrey; Lucio Cocco; Alberto M Martelli
Journal:  Mol Pharmacol       Date:  2008-06-24       Impact factor: 4.436

10.  DNA-AP sites generation by etoposide in whole blood cells.

Authors:  Emilio Rojas; Patricia Mussali; Efrain Tovar; Mahara Valverde
Journal:  BMC Cancer       Date:  2009-11-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.